EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

20 7 2023 18:03:20 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces CEO Transition

27 6 2023 07:55:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

15 5 2023 07:58:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

11 5 2023 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For First Quarter 2023

09 5 2023 16:05:02 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

19 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

29 3 2023 09:48:20 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

27 2 2023 16:42:44 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

15 2 2023 17:19:50 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

15 2 2023 02:00:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 2 2023 16:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

09 1 2023 06:59:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

05 1 2023 17:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

06 12 2022 06:00:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

14 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

08 11 2022 16:16:51 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

01 11 2022 16:05:14 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

18 10 2022 06:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

26 9 2022 16:12:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

06 9 2022 06:30:00 提供 Nasdaq GlobeNewswire